Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CP Board Review - Hematology > Coagulation and Clotting > Flashcards

Coagulation and Clotting Flashcards

0
Q

GPIa - GPIIa

A

Receptor for collagen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

GPIb

A

Receptor for Von willebrand factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Platelet alpha granules

A

Fibrinogen, platelet derived growth factor, vWF, P-selectin, platelet factor 4 (PF4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Platelet dense granules

A

ADP, ATP, serotonin (5-HT), calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Thrombin promotes these in coagulation pathway

A 
Fibrinogen to fibrin
V to Va
XIII to XIIIa
VIII to VIIIa
XII to XIIa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Factors in extrinsic pathway

A

VII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Factors in intrinsic pathway

A

XII,XI,IX,VIII,prekallikrein, high molecular weight kininogen (HMWK)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Factors in common pathway

A

X,II (thrombin), I (fibrinogen)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tenase complex

A

Forms on surface of platelets.
IXa,VIIIa, calcium
Activates X to Xa
Intrinsic pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Anchors the Tenase and prothrombinase complexes to platelet

A

Phophatidleinositol and phophatidlyserine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Prothrombinase complex

A

Va and Xa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Antithrombin

A

Inactivates thrombin, IXa,Xa,XIa,XIIa

Stimulated by heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Activated protein c (APC)

A

Inactivates Va and VIIIa with protein S as cofactor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

tPA

A

Tissue plasminogen activator. Coverts plasminogen to plasmin. Released from vasculature endothelial cells with injury.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bleeding time

A

Elevated in Von Willebrand disease, other inherited platelet disorders, uremia, aspirin use, low platelet count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PFA-100

A

Instrument used for platelet disorder screening. Uses artificial vessel. Measures the time for anticoagulated whole blood to occlude aperture under standardized flow control. Aperture is covered with either col/epi or col/adp membrane. Adp membrane is sensitive to drug induced platelet defects (aspirin)

16
Q

Platelet aggregometry

A

Sample of platelet rich plasma stirred while being exposed to agonist including ADP,epinephrine, arachidonate, collagen, ristocetin. Turbid mixture clears with aggregation. Medication is most common reason for abnormal results.

Response to everything but ristocetin is hallmark of vWD.

18
Q

Activated clotting time

A

Point of care test to monitor high dose heparin therapy (aPTT is unmeasurable >150 seconds)

19
Q

Activated partial thromboplastin time (aPTT)

A

Phospholipid, a contact activator of factor XII (e.g., silica, kaolin), and excess calcium are added to citrated plasma. The tim to clot formation is the aPTT.

20
Q

Elevated PT, normal aPTT

A 
Factor VII
liver disease
Vitamin K deficiency
Warfarin
Inherited factor deficiency
21
Q

Normal PT, Elevated aPTT

A

Factors: VIII, IX, XI, XII, HMWK, prekallicrein, LAC

Clinical: Acquired inhibitors
Heparin
Lupus anticoagulant
Inherited factor deficiency

22
Q

Elevated PT, elevated aPTT

A

Factors: V, X, Fibrinogen, LAC

Clinical:
DIC
Heparin
Amyloidoisis (acquired factor X deficiency)
Liver disease
Prematurity
Polycythemia
Inherited factor dificiency
23
Q

Normal PT, Normal aPTT

A

XIII, LAC

Bleeding (with XIII)
Normal or thrombophilic (with LAC)

24
Q

Anti-Xa assay (heparin antifactor Xa assay)

A
  • used to monitor either unfractionated or low molecular weight heparin (LMWH).
  • test of choice for monitoring LMWH and danaparoid
  • patient’s plasma is added to a known amount of factor Xa with excess antithrombin. Heparin in the patient’s plasma stimulates antithromin to inhibit factor Xa. The quantity of residual factor Xa is measured with a chromogenic substrate which Xa cleaves to produce a colored compound that is detected by a spectrophotometer. The residual Xa is subtracted from the initial Xa to determine the anticoagulant concentration. Thus when there has been no heparin administered, the anti factor Xa should be zero The higher the heparin, the higher the anti factor Xa.
25
Q

Bethesda assay

A
  • also called factor VIII inhibitor assay, anti-factor VIII antibody assay
  • Factor VIII is the most common factor to which antibodies arise
  • can be adapted to any factor
  • Anti-factor VIII antibodies have characteristic properties
  • they behave as inhibitors in coagulation screen assays (fails to correct with 1:1 mix, especially after 1-4 hour incubation - time dependance)
  • if factor assays are performed, factor VII will appear decreased and serial dilutions wills how progressively more factor VIII activity

procedure:

  • make several dilutions of patient plasma with citrated saline
  • each mixed 1:1 with normal plasma and incubated for 1-2 hours
  • Factor VIII activity assays are then performed on each dilution
  • the dilution at which the factor VIII activity is 50% represents the inhibitor titer.
  • Bethesda units are the dilution factor for 50% activity (e.g.. 1:16 = 16 Bethesda units)
  • 5 the antibody cannot be overcome with high doses of human factor VIII. (use porcine factor VIII, activated prothrombin complex concentrate APCC, or recombinant factor VII NovoSeven
26
Q

D-dimer & fibrin-degradation products (FDPs)

A
  • D-dimers are formed by factor XIII when it cross links D regions of fibrin molecules
  • later, the fibrin clot is disassembled by plasmin, which is incapable of breaking up D-dimers
  • NOT formed in the plasmin-mediated degradation of fibrinogen, but rather released into circulation
  • Presence of D-dimer indicates that fibrin has been formed and then degraded
  • Assays for FDPs are a little less specific because they detect fibrin degrading products, fibrinogen degradation products, and D-dimer
  • most often increased in thrombosis and significant bleeding
  • may be elevated in atrial fibrillation and CHF
  • cirrhotic patients may have persistent elevation because of difficulty clearing
  • some cancers cause elevation (mucin-secreting adenocarcinomas)
  • DIC
  • widely applied to the diagnosis of venous thromboembolism and PE, negative predictive value is most useful, especially in patients with low pretest probability
27
Q

Factor assays

A
  • II, V, VII, VIII, IX, X, XI, XII
  • patient plasma is mixed with reagent plasma having a known factor deficiency
  • resulting PT or PTT is compared to standard curve, generated by plotting known factor levels against clotting times.
  • Factor VIII, IX, XI, and XII assays are PTT based
  • Factor II, VII, and X assays are PT based
  • Factor V can be either
  • serial dilutions are usually used
  • an inhibitor is suggested if serial dilutions result in an apparent increase in factor activity
  • isolated inherited factor deficiencies are less common than multiple acquired factor deficiencies (DIC, liver disease, coumadin)
28
Q

Fibrinogen activity

A
  • very similar to Thrombin time assay
  • excess thrombin is added to diluted patient’s plasma
  • use standard curve to determine activity
29
Q

von Willebrand Dz Types

A

Type 1

  • quantitative decrease in vWF
  • mild to moderate bleeding
  • most common 70-80% of cases
  • normal molecules of factor

Type 2

  • qualitative deficiencies with functional abnormalities of vWF
  • quantity is often reduced too
  • 20-30% of cases
  • can be severe bleeding, but usually mild to moderate
  • Four subtypes
  • 2A - loss of high-molecular-weight multimers (defective assembly and secretion, or increased rate of proteolyzed)
  • 2B - mutations lead to increased binding of vWF to GP1b (platelet receptor) and resulting increased clearance of factor and platelets
  • “Platelet type” or “pseudo vWD” is rare disorder that is similar to type 2B, except the mutation in on the platelet GP1b gene instead of VWF gene. leads to increased binding and increased clearance
  • 2M - decreased function with normal sized multimers. impaired binding of vWF to GP1b
  • 2N - (normandy) mutations are located withing factor VIII binding site. Factor VIII half-life is shorter. vWF is normal. Often misdiagnosed as hemophilia A

Type 3

  • severe bleeding
  • very rare .5- 5.3 per million
  • quantitative deficiency so severe that vWF is often undetectable

CP Board Review - Hematology (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions